Here are five quick key notes:
1. The five analysts gave the company an average broker rating score of 1.00 — a “strong buy.”
2. The 12-month consensus target price was set at $26.33.
3. The analysts expect the company to post $0.23 earnings per share for the current quarter.
4. K2M traded down 0.36 percent on Tuesday, hitting $24.85.
5. The market cap is $985.43 million.
Northland Securities also recently initiated coverage on the company, setting the price target at $31 and rating the company as “outperform.”
More articles on orthopedic devices:
6 key trends in the North American joint reconstruction market
Orchid opens new India plant—5 things to know
8 trends in the China orthopedic instrument market
